This protocol applies to patients with sporadic mesenteric desmoid tumor who do not have underlying familial adenomatous polyposis (FAP). The mesenteric location carries specific clinical risks, and the initial strategy reflects the evidence for this population.

Clinical Scenario

Patients with sporadic mesenteric desmoid tumor may present with gastrointestinal complications — including bleeding, bowel obstruction, or tumor abscess — at diagnosis, during follow-up, or in the course of management. The absence of FAP distinguishes this population and shapes the therapeutic approach.

Initial Approach

The recommended first-line strategy in this setting is a structured observational approach, initiated before any active treatment decision. The full protocol specifies the framework, evaluation intervals, and the criteria that guide next steps.

Treatment Goals

The primary objective is stable tumor size on imaging. Clinically significant growth is defined by size increase documented at multiple consecutive follow-up timepoints — particularly when it threatens quality of life, function, or the viability of future treatment options.

References

DOI: 10.1001/jamaoncol.2024.1805

First, patients with sporadic mesenteric DT may present with gastrointestinal complications of bleeding, bowel obstruction, or tumor abscess either at diagnosis, during active surveillance, or while undergoing medical therapy.
However, a period of active surveillance should be proposed as the initial strategy for all patients with DT, before making any decision in favor of active treatment.
Persistent tumor growth was ascertained by observing tumor size increase at multiple (>2) consecutive follow-up appointments, threatening quality of life (QOL), life, or function or posing a potential risk to the feasibility or effectiveness of first-line treatment.

View source ↗

Mesenteric Desmoid Tumor Without Familial Adenomatous Polyposis: First-Line Management

References